Colorectal neoplasms Trials in Seoul, South Korea
Conditions / Colorectal neoplasms / Seoul, South Korea
Colorectal neoplasms is a medical condition with active clinical research programs worldwide.
28 total trials for this combination
Showing top 10 of 28 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00561470 | Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen | COMPLETED | PHASE3 |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | ACTIVE_NOT_RECRUITING | — |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | RECRUITING | PHASE3 |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | RECRUITING | PHASE1/PHASE2 |
| NCT02149108 | Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) | COMPLETED | PHASE3 |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | RECRUITING | PHASE3 |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT05328908 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer | TERMINATED | PHASE3 |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | RECRUITING | PHASE3 |